169 related articles for article (PubMed ID: 8592432)
1. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
2. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
Gelin J; Moldawer LL; Lönnroth C; Sherry B; Chizzonite R; Lundholm K
Cancer Res; 1991 Jan; 51(1):415-21. PubMed ID: 1703040
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
4. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
5. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and whole-body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1993 Jul; 53(3):180-3. PubMed ID: 8331940
[TBL] [Abstract][Full Text] [Related]
7. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
8. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
10. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
11. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats.
Sakaguchi Y; Makino M; Kaneko T; Stephens LC; Strebel FR; Danhauser LL; Jenkins GN; Bull JM
Cancer Res; 1994 Apr; 54(8):2223-7. PubMed ID: 8174130
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of interleukin 1 alpha in combination with hyperthermia.
Song CW; Lin JC; Lyons JC
Cancer Res; 1993 Jan; 53(2):324-8. PubMed ID: 8417825
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.
Edwards MJ; Heniford BT; Klar EA; Doak KW; Miller FN
J Clin Invest; 1992 Aug; 90(2):637-41. PubMed ID: 1644928
[TBL] [Abstract][Full Text] [Related]
16. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
17. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
18. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.
Van Lent PL; Van De Loo FA; Holthuysen AE; Van Den Bersselaar LA; Vermeer H; Van Den Berg WB
J Rheumatol; 1995 Dec; 22(12):2250-8. PubMed ID: 8835558
[TBL] [Abstract][Full Text] [Related]
19. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
20. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
Cahlin C; Körner A; Axelsson H; Wang W; Lundholm K; Svanberg E
Cancer Res; 2000 Oct; 60(19):5488-93. PubMed ID: 11034092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
